Journal of the American Academy of Dermatology
Tacrolimus Ointment: Advancing the Treatment of Atopic DermatitisThe impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis☆,☆☆,★,★★,♢
Section snippets
Study design
The QOL evaluations were conducted during 3 phase 3, randomized, double-blind, multicenter studies. The studies compared two concentrations of topical tacrolimus ointment (0.03% and 0.1%) with a vehicle control ointment in adult and pediatric patients with moderate to severe atopic dermatitis based on criteria developed by Rajka and Langland.15 The study drug was administered for up to 12 weeks or until 1 week after the affected areas defined for treatment at baseline were completely cleared,
Patient population
A total of 985 patients enrolled in the clinical studies. Between 90% and 94% of patients within each age group completed both a baseline and at least one subsequent QOL assessment and thus were included in the treatment effects analysis. Sample sizes in each age group included 579 adults, 178 children, and 145 toddlers. Baseline demographics and clinical severity were comparable across treatment groups in each age group. The average ages for the adults, children, and toddlers were 39 years, 9
Discussion
The findings from the analysis of the QOL data obtained from 3 prospective, randomized, double-blind, multicenter studies demonstrated that topical tacrolimus ointment is associated with significant QOL benefits in adult and pediatric patients with atopic dermatitis. The QOL benefits were observed across all QOL categories measured, including symptoms, feelings, daily activities, sleep, and treatment impact.
In each age group, the improvements associated with tacrolimus ointment were quite
Conclusions
This study demonstrated that atopic dermatitis can be quite burdensome on patients' QOL and that topical tacrolimus ointment is associated with significant QOL improvements in both adult and pediatric patients with atopic dermatitis. More than 60% of adults, children, and toddlers receiving tacrolimus ointment improved in areas in which atopic dermatitis has the most impact, including itchiness/pain, self-consciousness, being upset/sad, working/studying, and sleeping. QOL benefits of tacrolimus
References (18)
- et al.
Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample
J Am Acad Dermatol
(1986) - et al.
Cyclosporine in severe childhood atopic dermatitis: a multicenter study
J Am Acad Dermatol
(1996) - et al.
Guidelines of care for atopic dermatitis
J Am Acad Dermatol
(1992) Essential aspects of atopic dermatitis
Monogr Allergy
(1987)Pharmacophysiology of atopic dermatitis
Clin Rev Allergy
(1986)- et al.
Secular change in the occurrence of atopic dermatitis
Acta Derm Venereol Suppl (Stockh)
(1992) - et al.
Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use
Clin Exp Dermatol
(1994) - et al.
Improved discriminative and evaluative capability of a refined version of the Skindex, a quality-of-life instrument for patients with skin diseases
Arch Dermatol
(1997) - et al.
Dermatology quality of life scales: a measure of the impact of skin diseases
Br J Dermatol
(1997)
Cited by (0)
- ☆
Supported by an educational grant from Fujisawa Healthcare, Inc, Deerfield, Illinois.
- ☆☆
This article is part of a supplement sponsored by Fujisawa Healthcare, Inc.
- ★
Dr Drake's and Dr Breneman's institutions have received grant support from Fujisawa. Ms Prendergast, Dr Lawrence, Ms Maher, and Mr Matoi are employees of Fujisawa Healthcare, Inc. Dr Korman and Ms Beusterien are consultants for Fujisawa.
- ★★
Reprint requests: Lynn A. Drake, MD, Department of Dermatology, Massachusetts General Hospital, 40 Blossom Street—BAR604, Boston, MA 02114-2696.
- ♢
J Am Acad Dermatol 2001;44:S65-72.